Canadian International Pharma Corp. Launches PharmaCert Certification Program

West Vancouver, British Columbia, April 25, 2016 – Canadian International Pharma Corp. (the “Company” or “CIPC”) is pleased to announce that it has launched the PharmaCert Certification Program, a medication certification program using globally respected Canadian and US standards that measure the identity, strength, quality and purity of medications based on trusted standards, such as United States Pharmacopeia and British Pharmacopeia.

“The PharmaCert Certification Program was developed to provide drug and nutraceutical manufacturers, distributors and government regulators in developing countries the opportunity for their locally manufactured drugs to compete with national brands. We are pleased with the response we have received to date for this certification program. Stakeholders are recognizing how PharmaCert differentiates locally manufactured medications in their local and export markets from competing medications and national brands in a very positive way.  It enhances the reputation of both the manufacturer and its products and positions the medications at the level of well recognized generics and nutraceuticals made by reputable pharmaceutical companies.“ said Douglas L. Mason, CEO of Canadian International Pharma Corp.

PharmaCert can be used to certify any class of nutraceutical and pharmaceutical medications. Testing certifies that the ingredients claimed on the label and the formulation of the medication exist in the final product and that each ingredient has the concentration and potency as claimed on the product label.  Thus assuring its quality, safety, bioavailability and efficacy. The PharmaCert certification also ensures there are no unwanted, toxic or harmful ingredients in the tested medications. The PharmaCert certification assures consumers and government regulators in each country that the medication adheres to the highest level of standards and “GMP” (good manufacturing practices), as found in Canada and the US. For more information about the PharmaCert Program and how it works, visit the Company’s newly launched website at

“Many pharmaceutical manufacturers in developing countries have a limited market in their country of origin, and they rarely have the option of expanding and exporting the medications to other countries.  In many cases, the exportation of medications is a significant factor for bringing the high value of currency from other, more advanced countries to the country of origin.  Having the higher value currency in the country’s treasury is a meaningful economic tool for any country.  This would give a significant financial advantage to manufacturers,” said Dr. Mehrun Payravi, President of Canadian International Pharma Corp.  “As well, in many developing countries, governments give special privileges to manufacturers who do more exportation.  They may receive tax incentives, government trade credits and subsidies, and many more advantages,” said Dr. Payravi.

About Canadian International Pharma Corp.

Canadian International Pharma Corp. (“CIPC” or the “Company”) is an emerging multi-faceted pharmaceutical company that is in the process of developing generic and nutraceutical drug manufacturing, distribution and sales. CIPC has recently entered into a letter of intent to license the formulations of 99 nutraceutical and pharmaceutical medications.  Upon completion of a definitive agreement, and any regulatory approvals, the Company intends to pursue commercial agreements to produce and sell these medications.  CIPC has also recently launched its PharmaCert Program.  PharmaCert is a certification program for testing and measuring finished dosage forms of nutraceutical and pharmaceutical medications. The Company has also aligned itself with Canadian and US manufacturers with the objective of manufacturing generics and nutraceuticals for Canadian and overseas markets.

For further information, contact Mr. Clive Shallow, Shareholder Communications, at 604-922-2030, or visit the Company’s website at

“Douglas L. Mason”
Douglas L. Mason, Chief Executive Officer

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture Exchange) accepts responsibility for the adequacy of accuracy of this release.


This release includes certain statements that may be deemed “forward-looking statements” within the meaning of applicable securities legislation. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “suspects”, “intends”, “estimates”, “projects”, ”targets”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those expressed in, or implied by, this forward looking information.  Factors that could cause actual results to differ materially from those in forward-looking statements include such matters as market prices for the Company’s anticipated products, regulatory approvals required for the Company’s business plans, continued availability of capital and financing, and general economic, market or business conditions.  Any forward-looking statements are expressly qualified in their entirety by this cautionary statement.  Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date such statements were made. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.